Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Phathom Pharmaceuticals Raises FY2025 Sales Guidance from $165.000M-$175.000M to $170.000M-$175.000M vs $169.904M Est

Author: Benzinga Newsdesk | October 30, 2025 06:24am
Phathom Pharmaceuticals (NASDAQ:PHAT) raises FY2025 sales outlook from $165.000 million-$175.000 million to $170.000 million-$175.000 million vs $169.904 million estimate.

Posted In: PHAT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist